Two months ago, there was a mad rush to get the two oral antiviral pills approved to treat COVID-19. Pharmacies often ran out of these drugs within hours of delivery. Now, no one wants them. What is going on?
It's been an interesting month COVID-wise. The COVID antivirals made their way to pharmacies. All in all, things went pretty well (unless you happen to be Merck). Here, you'll learn how to locate pharmacies in your area that have been selected to carry the drugs, and how to see if the pills are in stock.
Patients and their doctors have voted with their scripts. Overwhelmingly, they are choosing Pfizer's Paxlovid and rejecting Merck's molnupiravir. So much so that when Paxlovid is unavailable (which is most of the time) many don't even bother to try the other option. Surprising?
We Have New Covid Drugs- FDA Needs to Get Out of the Way. Drs. Singer and Bloom in the NY Daily News
Two newly-approved antiviral drugs against COVID are now available to those who need them. But the FDA is getting in the way with unwise and counterproductive requirements. Drs. Jeffrey Singer and Josh Bloom explain in their Op Ed in the New York Daily News.
All of a sudden we have two (provisionally) FDA-approved COVID antivirals, which will be in pharmacies soon. They are quite different. Which is best for you?
It was pretty much a forgone conclusion, but the FDA's decision to grant an Emergency Use Authorization to Pfizer's COVID drug, Paxlovid, could mark the turning point in our battle against the virus. Here's the story that you won't find anywhere in the press.
Merck just announced that it granted a royalty-free license for its antiviral drug molnupiravir to Medicines Patent Pool, a United Nations-backed organization dedicated to providing crucial medicines to 105 poorer countries. Will this make a difference in the battle against COVID? I argue that it will.
Emergency Use Authorization (EUA) from the FDA is the exception, not the rule. Except for COVID therapies. Three vaccines and one drug have EUA in the US. Merck is now seeking EUA for its antiviral drug molnupiravir. Should it be granted?
A group at Sloan Kettering is proposing the use of certain types of chemotherapy drugs to treat SARS-CoV-2 infection. One cannot help thinking of the old adage about what everything looks like when you only have a hammer.
A Medscape article entitled "Five-Day Course of Oral Antiviral Appears to Stop SARS-CoV-2 in Its Tracks" was recently published. Don't fall for the title. It's not that simple.